Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013 : a collaborative analysis of cohort studies. / Trickey, Adam; May, Margaret T.; Vehreschild, Jorg Janne; Obel, Niels; Gill, M. John; Crane, Heidi M.; Boesecke, Christoph; Patterson, Sophie; Grabar, Sophie; Cazanave, Charles; Cavassini, Matthias; Shepherd, Leah; Monforte, Antonella d.Arminio; van Sighem, Ard; Saag, Mike; Lampe, Fiona; Hernando, Vicky; Montero, Marta; Zangerle, Robert; Justice, Amy C.; Sterling, Timothy; Ingle, Suzanne M.; Sterne, Jonathan A.C.; The Antiretroviral Therapy Cohort Collaboration.
I: The Lancet HIV, Bind 4, Nr. 8, 01.08.2017, s. e349-e356.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013
T2 - a collaborative analysis of cohort studies
AU - Trickey, Adam
AU - May, Margaret T.
AU - Vehreschild, Jorg Janne
AU - Obel, Niels
AU - Gill, M. John
AU - Crane, Heidi M.
AU - Boesecke, Christoph
AU - Patterson, Sophie
AU - Grabar, Sophie
AU - Cazanave, Charles
AU - Cavassini, Matthias
AU - Shepherd, Leah
AU - Monforte, Antonella d.Arminio
AU - van Sighem, Ard
AU - Saag, Mike
AU - Lampe, Fiona
AU - Hernando, Vicky
AU - Montero, Marta
AU - Zangerle, Robert
AU - Justice, Amy C.
AU - Sterling, Timothy
AU - Ingle, Suzanne M.
AU - Sterne, Jonathan A.C.
AU - The Antiretroviral Therapy Cohort Collaboration
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. Methods We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996–99, 2000–03 [comparator], 2004–07, 2008–10). We estimated life expectancy by calendar period of initiation of ART. Findings 88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008–10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000–03 (adjusted HR 0·71, 95% CI 0·61–0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008–10 than in those who started in 2000–03 (0·57, 0·49–0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008–10 (vs 2000–03) in the first year (0·48, 0·34–0·67) and second and third years (0·29, 0·21–0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men. Interpretation Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements. Funding UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme.
AB - Background Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. Methods We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996–99, 2000–03 [comparator], 2004–07, 2008–10). We estimated life expectancy by calendar period of initiation of ART. Findings 88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008–10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000–03 (adjusted HR 0·71, 95% CI 0·61–0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008–10 than in those who started in 2000–03 (0·57, 0·49–0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008–10 (vs 2000–03) in the first year (0·48, 0·34–0·67) and second and third years (0·29, 0·21–0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men. Interpretation Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements. Funding UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme.
U2 - 10.1016/S2352-3018(17)30066-8
DO - 10.1016/S2352-3018(17)30066-8
M3 - Journal article
C2 - 28501495
AN - SCOPUS:85019165975
VL - 4
SP - e349-e356
JO - The Lancet HIV
JF - The Lancet HIV
SN - 2352-3018
IS - 8
ER -
ID: 196467646